Gouvernance Gilead Sciences, Inc. Mexican S.E.

GILD *

US3755581036

Produits pharmaceutiques

Cours en clôture Mexican S.E. Autres places de cotation 25/06/2026			Varia. 5j.	Varia. 1 janv.
2 203,81 ^MXN	-0,28%		+4,15%	-0,83%

25/06	Les grandes fusions-acquisitions dans le secteur pharmaceutique et biotechnologique aux États-Unis depuis dix ans	RE
24/06	Gilead affirme que la FDA approuve Trodelvy en traitement de première ligne du cancer du sein triple négatif avancé	MT

Comité Exécutif: Gilead Sciences, Inc.

Dirigeant

Fonctions occupéesDepuis

Daniel O'Day

61 ans

Chief Executive Officer

01/03/2019

Erin Burkhart

57 ans

Comptroller/Controller/Auditor

22/09/2025

Dietmar Berger

63 ans

Chief Tech/Sci/R&D Officer

02/01/2025

Sarah Miksinski

General Counsel

Jacquie Ross

Investor Relations Contact

01/01/2021

Jyoti Mehra

50 ans

Human Resources Officer

01/11/2017

Andrew Dickinson

56 ans

Director of Finance/CFO

01/11/2019

Keeley Wettan

Compliance Officer	18/12/2025
General Counsel	18/12/2025
Corporate Secretary	18/12/2025

Composition du Conseil d'Administration: Gilead Sciences, Inc.

Administrateur

ComitésDepuis

Daniel O'Day

61 ans

Chairman

01/03/2019

Kelly Kramer

58 ans

Compensation Committee	01/12/2020
HR Committee
Audit Committee Chair
Audit Committee	01/02/2020
Governance Committee	01/02/2020
Nominating Committee	01/02/2020

Harish Manwani

72 ans

Compensation Committee	09/05/2018
HR Committee	09/05/2018
Governance Committee Chair	12/05/2021
Nominating Committee Chair	12/05/2021

Anthony Welters

71 ans

Governance Committee	12/05/2021
Nominating Committee	12/05/2021
Compensation Committee Chair	17/10/2020
HR Committee Chair	17/10/2020

Ted Love

67 ans

Governance Committee Chair
Nominating Committee Chair
Compensation Committee Chair	03/08/2023
Audit Committee	01/12/2025

Sandra Horning

77 ans

Governance Committee	13/11/2020
Nominating Committee	13/11/2020

Jacqueline Barton

73 ans

Compensation Committee	01/01/2018
HR Committee	01/01/2018

Javier Rodriguez

65 ans

Audit Committee

15/06/2020

Jeffrey Bluestone

72 ans

Executive Committee

09/04/2020

Anciens Dirigeants et Administrateurs: Gilead Sciences, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Kevin Lofton

Director/Board Member	29/07/2009	08/05/2024
Independent Dir/Board Member	29/07/2009	08/05/2024

Brett Pletcher

Compliance Officer	-	01/08/2022
General Counsel	31/03/2011	01/08/2022
Corporate Officer/Principal	01/01/2005	31/03/2011
Corporate Secretary	-	01/08/2022

Tai Yin Yang

Corporate Officer/Principal

01/01/2005

18/07/2022

Amy Flood

Public Communications Contact

01/06/2021

William Lee

Chief Tech/Sci/R&D Officer

01/01/1991

12/04/2021

Richard Whitley

Director/Board Member	01/07/2008	01/01/2021
Independent Dir/Board Member	01/07/2008	01/01/2021

Robin Washington

Comptroller/Controller/Auditor	05/05/2008	01/11/2019
Director of Finance/CFO	05/05/2008	01/11/2019

Gregg Alton

Chief Executive Officer	01/01/2019	01/03/2019
Compliance Officer	01/01/1999	-
Public Communications Contact	04/08/2009	09/05/2012
General Counsel	01/01/1999	04/08/2009
Corporate Officer/Principal	01/03/2019	04/10/2019
Corporate Secretary	01/01/1999	-

John McHutchison

Chief Tech/Sci/R&D Officer	01/03/2018	02/08/2019
Corporate Officer/Principal	08/06/2010	01/03/2018

John Martin

Chief Executive Officer	01/01/1996	10/03/2016
Chairman	01/06/2008	01/03/2019

John Milligan

Director/Board Member	28/01/2016	31/12/2018
Chief Executive Officer	10/03/2016	31/12/2018
Chief Operating Officer	01/01/2007	10/03/2016
Director of Finance/CFO	01/01/2002	01/01/2007
President	01/01/2008	31/12/2018

Andrew Cheng

Chief Tech/Sci/R&D Officer	-	07/09/2018
Corporate Officer/Principal	01/01/1999	-

Norbert W. Bischofberger

Chief Tech/Sci/R&D Officer	01/01/1995	30/04/2018
Corporate Officer/Principal	01/08/1990	01/01/1995

James Meyers

Corporate Officer/Principal

01/01/1996

22/02/2018

John Madigan

Director/Board Member	01/12/2005	10/05/2017
Independent Dir/Board Member	22/07/2011	10/05/2017

Paul Carter

Corporate Officer/Principal

01/04/2006

01/08/2016

Kevin Young

Corporate Officer/Principal	01/09/2004	04/02/2014
Chief Operating Officer	24/05/2016	-

Gordon Earle Moore

Director/Board Member	01/01/1996	31/05/2013
Independent Dir/Board Member	22/07/2011	31/05/2013

James M. Denny

Director/Board Member	01/01/1996	31/05/2013
Independent Dir/Board Member	22/07/2011	31/05/2013

Susan T. Hubbard

Investor Relations Contact

01/09/1989

01/06/2012

Alan Montgomery

Corporate Officer/Principal

01/08/2006

01/05/2011

Anthony D. Caracciolo

Corporate Officer/Principal

01/01/1997

01/10/2010

Per Wold-Olsen

Director/Board Member	28/01/2010	-
Independent Dir/Board Member	28/01/2010	-

Louis Lange

Corporate Officer/Principal

20/04/2009

Seigo Izumo

Corporate Officer/Principal

01/09/2008

Caroline Dorsa

Director of Finance/CFO

05/11/2007

17/01/2008

Howard Rosen

Corporate Officer/Principal

01/01/2004

01/01/2008

Carla A. Hills

Director/Board Member	01/01/2007	-
Independent Dir/Board Member	22/07/2011	-

Steven Fife

Comptroller/Controller/Auditor

01/01/2005

01/01/2006

Kristen M. Metza

Human Resources Officer

01/01/2006

John Francis Cogan

Director/Board Member	01/07/2005	-
Independent Dir/Board Member	01/07/2005	-

Nicholas G. Moore

Director/Board Member	01/03/2004	-
Independent Dir/Board Member	01/03/2004	-

Karl G. Trass

General Counsel

01/01/2003

01/07/2003

James Sapirstein

Sales & Marketing

01/06/2000

01/06/2002

Michael W. Aguiar

Director of Finance/CFO

01/01/2002

Rebecca Coleman

Director/Board Member

02/01/2000

Robert L. Simon

General Counsel

01/07/2000

01/12/2001

Gayle Edlund Wilson

Director/Board Member	01/10/2001	-
Independent Dir/Board Member	01/10/2001	-

Kenneth Cundy

Corporate Officer/Principal

01/01/1992

01/01/2000

Jeff Bird

Corporate Officer/Principal

01/01/2000

Mark D. Matteucci

Corporate Officer/Principal

01/01/1988

01/01/1999

Louis C. Bock

Corporate Officer/Principal

01/09/1989

Robert J. Stagg

Chief Tech/Sci/R&D Officer

01/08/1993

01/12/1996

George Pratt Shultz

Director/Board Member

01/01/1996

Michael Bigham

Chief Operating Officer	01/01/1988	01/01/1996
Director of Finance/CFO	01/01/1988	01/01/1996

Bill Harris

Director of Finance/CFO

01/01/1990

01/01/1996

John Latham

Corporate Officer/Principal

01/01/1989

01/01/1994

Étienne Francois Davignon

Director/Board Member	01/09/1990	-
Independent Dir/Board Member	22/07/2011	-

John J. Toole

Corporate Officer/Principal

01/04/1990

Patrick O'Brien

Investor Relations Contact

Dirk B. Mendel

Corporate Officer/Principal

Sunil Patel

Corporate Officer/Principal

Gulshan Shaver

Corporate Officer/Principal

Akram Bouchenaki

Corporate Officer/Principal

Joseph M. Baini

Corporate Officer/Principal

James V. Desiderio

Corporate Officer/Principal

Wenjin Yang

Corporate Officer/Principal

Gary C. Visor

Corporate Officer/Principal

Mark Italia

General Counsel

Robert L. St. Claire

Corporate Officer/Principal

David Brogan

Corporate Officer/Principal

Jeffery P. Davis

Corporate Officer/Principal

Jeffrey Rudy

Corporate Officer/Principal

Pamela Goss

Corporate Officer/Principal

Nicholas S. Hellmann

Corporate Officer/Principal

Adam Tomasi

Corporate Officer/Principal

Cordell W. Hull

Director/Board Member

Roger Mills

Corporate Officer/Principal

Richard J. Gorczynski

Corporate Officer/Principal

Erin Edgley

Public Communications Contact

George Tidmarsh

Corporate Officer/Principal

Julie Cherrington

Corporate Officer/Principal

Jim Ziegler

Corporate Officer/Principal	-	-
Sales & Marketing	-	-

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	15
Femme	9

Dont comité exécutif

Homme	4
Femme	4

Dont Administrateurs

Homme	8
Femme	1

Révisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Non

Controverses sur les droits de l'Homme

Non

Controverses Subventions fiscales

Non

Conforme à la finance Islamique

Non

Gilead Sciences, Inc. est spécialisé dans le développement, la fabrication et la commercialisation de produits thérapeutiques. Le CA par source de revenus se répartit comme suit : - ventes de médicaments (98,2%) : destinés au traitement du VIH (71,8% du CA), des maladies d'oncologie (11,2%), du virus de l'hépatite B (11,1%), du virus de l'Ebola (3,2%) et autres (2,7% ; notamment rétinites à cytomégalovirus et sarcome de Kaposi avancé résultants du VIH) ; - autres (1,8%) : notamment royalties et revenus issus des prestations de recherche et développement et de la fabrication en sous-traitance de produits thérapeutiques. La répartition géographique du CA est la suivante : Etats-Unis (70,9%), Europe (17,2%) et autres (11,9%).

Employés

17 000

Secteur

Produits pharmaceutiques

Plus d'informations sur la société